News Sentiment

KPTI sentiment intelligence

Karyopharm Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 61 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 10.34 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

78/100 classification confidence.

Company focus 53

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

+7.7% over one week, +8.8% over four weeks, trend active, and near fair-value range.

Latest direct headline Neutral

KPTI5813817 Bond Risk Profile

Market Reaction

Price moving ahead of tone

62/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 78/100 classification
One-week reaction 7.7% Price confirming higher
Trend fit Trend active 8.8% over four weeks
Fair value -6.7% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 15
Neutral 42
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 53
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 11
TradingView 8
Karyopharm 7
PR Newswire 7
simplywall.st 5
Quartr 3
Finviz 3
TradingKey 3

Event Lens

What the news is about

Classified themes
Market update 30
Earnings 21
Analyst action 8
Deals and strategy 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 61
TradingView Direct company coverage

KPTI5813817 Bond Risk Profile

This article provides a bond risk profile for Karyopharm Therapeutics Inc.'s 6.0% bond, KPTI5813817, due May 13, 2029. It highlights key metrics for credit risk assessment, including security level, inflation protection, and issuer rating, to help investors evaluate reliability.

Tone
Neutral 50/100
Event
Analyst action
Published
14 Jul 2026 03:11
Source
TradingView
TradingView Direct company coverage

KPTI5813817 Bond Profile — Key Metrics

This article provides a bond profile for Karyopharm Therapeutics Inc.'s KPTI5813817 bond, detailing key metrics such as a 6.0% coupon rate and a May 13, 2029 maturity date. The company, founded in 2008, is a commercial-stage pharmaceutical company focused on cancer and other dise

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 21:42
Source
TradingView
Moomoo Direct company coverage

RBC Capital Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Maintains Target Price $16

RBC Capital has reiterated its Buy rating for Karyopharm Therapeutics (KPTI.US), maintaining a target price of $16. This indicates the firm's continued positive outlook on the company's stock performance and valuation. The maintained ratings suggest that RBC Capital perceives ong

Tone
Positive 73/100
Event
Analyst action
Published
09 Jul 2026 07:40
Source
Moomoo
Quartr Direct company coverage

Karyopharm Therapeutics (KPTI) Q2 2024 earnings summary

Karyopharm Therapeutics (KPTI) reported a strong Q2 2024, achieving a net income of $23.8 million, a significant turnaround from a net loss in Q2 2023, primarily due to a non-cash gain on debt extinguishment. Total revenue grew to $42.8 million, driven by increased license and mi

Tone
Positive 82/100
Event
Earnings
Published
08 Jul 2026 18:10
Source
Quartr
Quartr Direct company coverage

Karyopharm Therapeutics (KPTI) Q4 2024 earnings summary

Karyopharm Therapeutics (KPTI) reported total revenue of $145.2M in 2024, with U.S. XPOVIO net product revenue at $112.8M, and a reduced net loss of $76.4M. The company is advancing pivotal phase III clinical trials with key data readouts expected in 2025 and 2026, and anticipate

Tone
Neutral 50/100
Event
Earnings
Published
08 Jul 2026 17:40
Source
Quartr
Quartr Direct company coverage

Karyopharm Therapeutics (KPTI) Q1 2025 earnings summary

Karyopharm Therapeutics released its Q1 2025 earnings summary, highlighting progress in its Phase 3 SENTRY trial for myelofibrosis, which passed futility analysis and is expected to complete enrollment by mid-2025 with top-line data anticipated late 2025/early 2026. Despite a dec

Tone
Neutral 50/100
Event
Earnings
Published
08 Jul 2026 17:40
Source
Quartr
Finviz Direct company coverage

KPTI - Karyopharm Therapeutics Inc Latest SEC Filings

This page provides the latest SEC filings for Karyopharm Therapeutics Inc (KPTI), along with a comprehensive overview of its financial data, market performance metrics, insider transactions, and analyst recommendations. Key figures included are market capitalization, sales, incom

Tone
Neutral 50/100
Event
Analyst action
Published
06 Jul 2026 16:42
Source
Finviz
Karyopharm Direct company coverage

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm Therapeutics Inc. announced it granted an aggregate of 1,649 restricted stock units (RSUs) to four newly-hired employees on June 30, 2026. These RSU awards, made under the Company's 2022 Inducement Stock Incentive Plan, are material inducements for their employment as

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 06:11
Source
Karyopharm
Stock Titan Direct company coverage

Karyopharm gives 4 new hires stock awards vesting over 3 years

Karyopharm Therapeutics (Nasdaq: KPTI) granted 1,649 restricted stock units (RSUs) to four new employees on June 30, 2026, under its 2022 Inducement Stock Incentive Plan. These RSUs, designed to induce employment, will vest over three years, with 33 1/3% vesting annually, conting

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 19:39
Source
Stock Titan
Finviz Direct company coverage

KPTI - Karyopharm Therapeutics Inc Volatility & Greeks

This article provides a detailed financial snapshot of Karyopharm Therapeutics Inc (KPTI), including its stock performance, key financial metrics, and volatility data. It lists various ratios, growth rates, insider and institutional ownership, and analyst recommendations. The dat

Tone
Neutral 50/100
Event
Analyst action
Published
01 Jul 2026 14:39
Source
Finviz
Finviz Direct company coverage

KPTI - Karyopharm Therapeutics Inc Dividends

This article provides detailed financial and stock performance data for Karyopharm Therapeutics Inc. (KPTI). It includes various financial metrics such as market cap, income, sales, EPS, and insider ownership, alongside stock performance indicators over different periods. The dat

Tone
Neutral 50/100
Event
Earnings
Published
01 Jul 2026 02:39
Source
Finviz
www.marketscreener.com Direct company coverage

Karyopharm Therapeutics Inc.(NasdaqGS:KPTI) added to Russell Small Cap Comp Growth Benchmark

Karyopharm Therapeutics Inc. (NasdaqGS: KPTI) has been added to the Russell Small Cap Comp Growth Benchmark, as announced by S&P Capital IQ. The company is a commercial-stage pharmaceutical firm focused on developing and commercializing drugs that inhibit nuclear export for cance

Tone
Positive 69/100
Event
Market update
Published
29 Jun 2026 20:40
Source
www.marketscreener.com
marketscreener.com Direct company coverage

Karyopharm Therapeutics Inc.(NasdaqGS: KPTI) added to Russell 2000 Index

Karyopharm Therapeutics Inc. (NasdaqGS:KPTI), a commercial-stage pharmaceutical company, has been added to the Russell 2000 Index. The company focuses on discovering, developing, and commercializing drugs targeting nuclear export for cancer treatment, with its lead asset XPOVIO (

Tone
Positive 71/100
Event
Market update
Published
29 Jun 2026 18:40
Source
marketscreener.com
marketscreener.com Direct company coverage

Karyopharm Therapeutics Inc.(NasdaqGS: KPTI) added to Russell 2000 Growth Benchmark

Karyopharm Therapeutics Inc. (NasdaqGS: KPTI) has been added to several Russell indices, including the Russell 2000 Growth Benchmark, Russell Small Cap Comp Growth Benchmark, Russell 2500 Growth Benchmark, and Russell 2000 Index. This inclusion follows a period of news regarding

Tone
Positive 70/100
Event
Market update
Published
29 Jun 2026 10:40
Source
marketscreener.com
www.marketscreener.com Direct company coverage

Karyopharm Therapeutics Inc.(NasdaqGS: KPTI) added to Russell 3000E Index

Karyopharm Therapeutics Inc. (NasdaqGS: KPTI) has been added to the Russell 3000E Index. The company is a commercial-stage pharmaceutical firm focused on developing drugs against nuclear export for cancer treatment. Its lead asset, XPOVIO (selinexor), is used for multiple myeloma

Tone
Positive 71/100
Event
Market update
Published
29 Jun 2026 06:41
Source
www.marketscreener.com
TradingView Direct company coverage

Enterprise value to EBITDA forward of Karyopharm Therapeutics Inc. – NASDAQ:KPTI

This article provides access to the enterprise value to EBITDA forward data for Karyopharm Therapeutics Inc. (NASDAQ: KPTI) on the TradingView platform. It highlights the company's financial overview within the pharmaceuticals sector, emphasizing data sources and intellectual pro

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 15:39
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Karyopharm Therapeutics Inc. – NASDAQ:KPTI

This article provides the "Price to sales forward" metric for Karyopharm Therapeutics Inc. (NASDAQ: KPTI). It is a short piece that simply presents this specific financial data point without further analysis or commentary. The content indicates "No trades" at the time of viewing,

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 10:09
Source
TradingView
TradingView Direct company coverage

Karyopharm Therapeutics, Inc. Actuals & Estimates (NASDAQ:KPTI)

This article provides an overview of Karyopharm Therapeutics Inc. (NASDAQ: KPTI) stock, including its current price, market capitalization, and analyst forecasts. It details historical stock performance, earnings per share, and revenue figures, along with upcoming earnings dates.

Tone
Positive 60/100
Event
Earnings
Published
25 Jun 2026 17:40
Source
TradingView
TradingView Direct company coverage

25K0 Forecast — Price Target — Prediction for 2027

This article provides a forecast for Karyopharm Therapeutics, Inc. (25K0) stock, including analyst price targets and ratings. It also offers key financial metrics such as EPS, revenue, net income, and EBITDA, along with frequently asked questions about the company's stock perform

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 17:40
Source
TradingView
TradingView Direct company coverage

KPTI Forecast — Price Target — Prediction for 2027

This article provides a comprehensive forecast for Karyopharm Therapeutics Inc. (KPTI) stock, including analyst price targets, historical performance, and financial metrics. It details the company's recent stock movements, earnings reports, revenue, market capitalization, and vol

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 14:40
Source
TradingView
Seeking Alpha Direct company coverage

Karyopharm: Xpovio Revenue Stagnation And Toxicity Concerns Justify Sell

Karyopharm Therapeutics receives a reiterated Sell rating due to ongoing clinical and commercial challenges with its drug selinexor (Xpovio). Stagnant Xpovio revenues of $115 million, coupled with toxicity issues and competition, undermine growth and adoption. Recent Phase 3 tria

Tone
Negative 28/100
Event
Analyst action
Published
18 Jun 2026 20:39
Source
Seeking Alpha
TradingKey Direct company coverage

Karyopharm Therapeutics Inc (KPTI) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Karyopharm Therapeutics Inc (KPTI), highlighting its current price momentum score, support and resistance levels, and various technical indicators and moving averages. The analysis suggests that KPTI is suitable for range-bound swing

Tone
Positive 59/100
Event
Market update
Published
18 Jun 2026 09:39
Source
TradingKey
TradingKey Direct company coverage

Karyopharm Therapeutics Inc (KPTI) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides a detailed breakdown of Karyopharm Therapeutics Inc (KPTI)'s shareholder structure, including its major individual shareholders and institutional holdings. It lists the top shareholders by proportion, categorizes shareholders by type (e.g., Hedge Fund, Inves

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 01:39
Source
TradingKey
TradingKey Direct company coverage

Karyopharm Therapeutics Inc (KPTI) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides historical data on dividends and stock splits for Karyopharm Therapeutics Inc (KPTI). It indicates that KPTI has distributed $0.00 in dividends over the past five years and lists several upcoming merger-related stock splits scheduled for February 24, 2025. T

Tone
Neutral 50/100
Event
Deals and strategy
Published
18 Jun 2026 01:39
Source
TradingKey
Investing.com UK Direct company coverage

Cantor Fitzgerald reiterates Overweight on Karyopharm stock

Cantor Fitzgerald has reiterated an Overweight rating on Karyopharm Therapeutics (NASDAQ:KPTI), following discussions with management about the potential of selinexor in endometrial cancer maintenance. The firm highlighted the unmet need in this area and how existing data de-risk

Tone
Positive 66/100
Event
Analyst action
Published
09 Jun 2026 13:09
Source
Investing.com UK